Material Agreement (Form 8-K)

Item 1.01. Entry into a Material Definitive Agreement.

On October 7, 2025, Spectrum Pharmaceuticals, Inc. ("Spectrum"), a wholly owned subsidiary of Assertio Holdings, Inc. (the "Company"), and Hanmi Pharmaceutical Co. Ltd. (the "Supplier") entered into an amendment and restatement (the "Amendment") of the Supply Agreement dated February 28, 2018, as previously amended, which provides for the supply of ROLVEDON drug substance to Spectrum (the "Agreement"). Among other things, the Amendment establishes long-term pricing following the expiration of the Agreement's fixed pricing provisions in October 2025.

The Amendment reflects a mid-single digit percentage reduction to the price Spectrum agreed to pay the Supplier for ROLVEDON drug substance following the Company's acquisition of Spectrum in 2023. Pursuant to the Amendment, the new price is fixed throughout the remaining term of Spectrum's license agreement with the Supplier, subject to (1) the Supplier's right to request price increases for periods beginning January 1, 2028, to the extent it experiences cost increases above a set threshold, and (2) a provision that reduces the per gram pricing by a specified amount for each year in which the previous year's global market volume for ROLVEDON exceeds a specified threshold which has not yet been met. Spectrum's consent is required for any changes to Supplier's manufacturing process. Accordingly, Spectrum may seek to negotiate a lower supply price as a condition to its approval of any future process improvements that lower the Supplier's costs.

Pursuant to the Amendment, Spectrum will also be required to provide the Supplier with a forecasted purchase plan each year. While there are no minimum purchase requirements, if Spectrum includes any orders in a forecasted purchase plan, it must designate at least fifty percent of such orders as binding. None of the Agreement's other supply terms were materially amended.

The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending December 31, 2025.